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DObjective: Transcatheter aortic valve implantation is a new method to treat high-risk patients with aortic valve
stenosis. The operative risk can be reduced, especially in patients with severely reduced left ventricular function
or cardiogenic shock. Nevertheless, this new procedure has some potential risks, especially during the phases of
rapid pacing (valvuloplasty and valve deployment). The use of cardiopulmonary bypass allows the perioperative
risk to be reduced.
Method: Between April 2008 and August 2011, 512 consecutive patients underwent transcatheter aortic valve
implantation. Cardiopulmonary bypass was used in 35 patients. In this special group, there were 17 men and 18
women with a mean age of 77 12 years (range, 38–92 years). Left ventricular ejection fraction was a mean of
32%  19% (range, 10%–70%), European System for Cardiac Operative Risk Evaluation was 60%  27%
(range, 13%–97%), and Society of Thoracic Surgeons’ mortality score was 35%  28% (range, 4%–90%).
Results: Cardiopulmonary bypass was used in 13 patients with preoperative cardiogenic shock, 11 patients with
impaired heart function during the procedure, 7 patients with severely impaired left ventricular function (left
ventricular ejection fraction, 17% 6%; range, 10%–30%), 3 patients with concomitant conventional surgical
procedures, and 1 patient with impaired right ventricular function. The technical success rate was 94%, 30-day
mortality was 20%, and 1-year survival was 46%.
Conclusions: The use of cardiopulmonary bypass enhances safety in critical transcatheter aortic valve implan-
tation procedures. Furthermore, transcatheter aortic valve implantation with cardiopulmonary bypass seems to
provide better results than medical therapy or conventional aortic valve replacement in critically ill patients. The
need for cardiopulmonary bypass emphasizes that the procedure should be performed only in cooperation be-
tween cardiologists and cardiac surgeons. (J Thorac Cardiovasc Surg 2013;145:757-63)Transcatheter aortic valve implantation (TAVI) has become
a standard procedure in multiple centers for high-risk pa-
tients with severe aortic stenosis.1-10 Although Walther
and colleagues1,2 showed that transapical aortic valve
implantation might reduce the risk of conventional
surgical aortic valve replacement in high-risk patients,
some authors recommend performing this new procedure
only in patients with a Society of Thoracic Surgeons’
(STS) mortality score less than 20%, a European System
for Cardiac Operative Risk Evaluation (euroSCORE) less
than 40%, and an expected survival of more than 1
year.11 However, the prognosis is grave for patients who
are not candidates for conventional aortic valve replace-
ment or TAVI.12e Deutsches Herzzentrum Berlin, Berlin, Germany.
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The Journal of Thoracic and CaAn alternative is to perform TAVI on cardiopulmonary
bypass (CPB). This procedure can be performed in patients
with severely depressed left ventricular function, an en-
larged right ventricle, or in cardiogenic shock. In addition,
previous heart surgery in this high-risk patient group will
not increase the perioperative risk.13 This study examines
the surgical procedure and postoperative course of patients
undergoing TAVI on CPB.PATIENTS AND METHODS
Patients
TAVI was performed between April 2008 and August 2011 in 512 pa-
tients at the Deutsches Herzzentrum Berlin, Germany. An Edwards SA-
PIEN valve (Edwards Lifesciences, Irvine, Calif) was implanted in 459
patients, and a CoreValve (Medtronic Inc, Minneapolis, Minn) was im-
planted in 53 patients. According to the individual patient risk profile,
a transapical access was chosen in 441 patients, a transfemoral access
was chosen in 56 patients, and a transaxillary access was chosen in 15 pa-
tients. The transapical route for aortic valve implantation was chosen espe-
cially in patients undergoing reoperation because it enables more precise
valve handling and positioning. The group of 512 patients was divided
into 2 groups according to whether the procedure was performed on elec-
tive CPB or not. Group I consisted of 35 patients in whom the TAVI pro-
cedure was performed on elective CPB. Group II served as controls and
consisted of 477 patients in whom the TAVI procedurewas performedwith-
out elective CPB.rdiovascular Surgery c Volume 145, Number 3 757
Abbreviations and Acronyms
CPB ¼ cardiopulmonary bypass
euroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
IABP ¼ intra-aortic balloon pump
LVEF ¼ left ventricular ejection fraction
PRIND ¼ prolonged reversible ischemic
neurologic deficit
STS ¼ Society of Thoracic Surgeons
TAVI ¼ transcatheter aortic valve
implantation
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Group I consisted of 35 patients (17 male and 18 female) with a mean
age of 77  12 years (range, 38–92 years). The left ventricular ejection
fraction (LVEF) was a mean of 32% 19% (range, 10%–70%), the euro-
SCOREwas 60% 27% (range, 13%–97%), and the STSmortality score
was 35%  28% (4%–90%). The procedure was performed in all these
patients on CPB. CPB was used in 13 patients with preoperative cardio-
genic shock, in 11 patients with impaired heart function during the proce-
dure, in 7 patients with severely impaired left ventricular function (LVEF,
17 6; range, 10%–30%), in 3 patients with planned concomitant conven-
tional surgical procedures, and in 1 patient with impaired right ventricular
function. Group II (control group) consisted of 477 patients in whom the
TAVI procedure was performed without the heart-lung machine. In this
group, therewere 185men and 292 womenwith a mean age of 80 8 years
(range, 29–99 years). The LVEF was a mean of 51% 13% (range, 10%–
70%), the euroSCORE was 35%  19% (range, 2%–95%), and the STS
mortality score was 16%  13% (1%–82%). In group I, significantly
more patients had pulmonary hypertension, the creatinine and pro-B-type
natriuretic peptide levels were significantly higher (Table 1), and the ejec-
tion fraction was significantly lower (Table 2). Therefore, the euroSCORE
and STS mortality score were significantly higher in group I (P< .05)
(Table 1).
Preoperative and Postoperative Evaluation
Pre- and postoperative examinations included clinical and laboratory
examinations, electrocardiogram, chest x-ray, transesophageal echocardi-
ography, and multislice computed tomography of the chest and pelvis fol-
lowed by vascular 3-dimensional reconstruction. Preoperative coronary
angiography and ultrasound examinations (Doppler) of the arteries and
veins of the lower extremities and of the carotid arteries were performed.
The Doppler examination allowed the detection of severe peripheral vascu-
lar disease. The echocardiographic data, postoperative course, potential
complications, and late outcome were followed.
Aims of the Elective Use of Cardiopulmonary Bypass
for Transcatheter Aortic Valve Implantation
According to our institutional policies,4 the elective use of cardiopulmo-
nary bypass was considered in patients with reduced ejection fraction
(<20%), presenting in cardiogenic shock (eg, catecholamine dependence,
organ failure, artificial ventilation), with a relevantly enlarged right ventri-
cle with pulmonary hypertension, or with a planned concomitant conven-
tional surgical procedure.4 TAVI was performed on elective CPB to
increase safety and hemodynamic stability during the procedure, and par-
ticularly to prevent manual cardiopulmonary resuscitation if ventricular fi-
brillation occurred during the TAVI procedure (in patients with poor left
ventricular function, enlarged right ventricle with reduced pulmonary758 The Journal of Thoracic and Cardiovascular Surgfunction, or cardiogenic shock). In addition, CPB allowed myocardial re-
covery of the unloaded heart in patients with shock.
Procedural and Technical Considerations
Immediately before the procedure, the whole team analyzed the diag-
nostic workup and discussed the possible technical difficulties and compli-
cations and means to prevent them. Elective coronary artery stent
implantation was considered in patients with concomitant coronary artery
disease.4,14 Only the most relevant coronary artery stenosis was considered
to be a target for stent implantation.4,14,15
The procedures were performed in a hybrid operating room in a com-
pletely sterile environment and under fluoroscopic imaging with a mono-
plane angiography system. All patients were under general anesthesia. The
surgical technique of transcatheter valve implantation was based on the pro-
cedure described by several authors,1-4with themodification of transcatheter
valve positioning and liberation under simultaneous angiography with
contrast medium to find the optimal valve position and reduce the risk of
paravalvular leakage.10 The procedure was monitored by fluoroscopy, angi-
ography, and intraoperative transesophageal echocardiography.
Cannulation for Elective Cardiopulmonary Bypass
The use of normothermic femoro-femoral CPBwas routinely considered
to provide a higher safety level during the procedure, and especially to pre-
vent manual cardiopulmonary resuscitation if ventricular fibrillation oc-
curred during TAVI. We routinely used an open surgical approach to the
femoral vessels, using a 15Fcannula to cannulate the common femoral artery
and a 23F cannula to cannulate the femoral vein (‘‘as small as possible’’) to
neutralize the risk of vascular complications. In the case of severe calcifica-
tion, the axillary artery was cannulated. A small (2–3 cm) incision in the
groin, parallel to the ligamentum inguinale Poupart, was chosen (and not
a classic vascular access to the femoral vessels). This incision enables easier
identification and faster and only limited dissection of thevessels, but special
attention was given to the ligation (by metallic clips) of the small lymphatic
tracts (to prevent postoperative lymphatic fistula). In the case of the transfe-
moral approach for TAVI, the artery of better quality was used for the TAVI
procedure and the other site was used for CPB cannulation. A fully percuta-
neous approach was not used to exclude the possible negative aspects of the
procedure itself and to achieve optimal access and hemostasis.
Technical Consideration of the Transcatheter Aortic
Valve Implantation Procedure During Elective
Cardiopulmonary Bypass
The guidewires and introducers were introduced via the left ventricular
apex into the left ventricle while a slight filling of the heart was achieved by
reducing the CPB drainage to maintain left ventricular ejection and facili-
tate initial passage of the guidewire through the stenotic aortic valve. If
complete unloading of the heart was possible, balloon dilatation of the na-
tive valve and valve deployment were performed without rapid pacing to
avoid possible ventricular fibrillation. If complete drainage and unloading
of the heart were not possible, rapid pacing was used for balloon valvulo-
plasty and valve release, and the left ventricle was drained as much as pos-
sible to prevent heart distension and ventricular fibrillation. Once adequate
deployment and function of the prosthesis had been achieved, the left ven-
tricular purse strings were tied and hemostasis was achieved. The prophy-
lactic transfemoral placement of an intra-aortic balloon pump (IABP) was
considered in patients with poor LVEF or cardiogenic shock to secure
greater safety and hemodynamic stability during the immediate postoper-
ative course.4 Then, weaning from CPB was performed.
Statistical Evaluation
All data analyses were performed using PASW Statistics, version 18.0
(SPSS, Inc, Chicago, Ill). The Gaussian distribution of the data was tested
by the Kolmogorov-Smirnov test. Depending on the result, theery c March 2013
TABLE 1. Patient data ([n]/% or mean ± standard deviation, range)
Group I Group II Test
No. of patients (n) 35 477
Sex (male/female) 17/18 185/292 P>.05*
Age (y) 78  12 (38–92) 79.6  8 (29–99) P>.05y
Weight (kg) 74  14 (44–115) 74  17 (37–147) P>.05y
Body mass index 27  4.7 (19–43) 27  5 (16–59) P>.05y
Comorbidity
Coronary heart disease 25 (71%) 282 (59%) P>.05*
Peripheral vascular disease 24 (69%) 329 (69%) P>.05*
Pulmonary hypertension (systolic>50 mm Hg) 22 (63%) 131 (27%) P ¼ .0001*
Chronic obstructive pulmonary diseasez 15 (43%) 231 (48%) P>.05*
Diabetes mellitus 8 (23%) 127 (27%) P>.05*
Previous surgery
CABG 6 (17%) 77 (16%) P>.05*
AVR 3 (9%) 21 (4%) P>.05*
MVS 3 (9%) 11 (2%) P>.05*
Apical descending conduit 1 (3%)x 0 P>.05*
Previous cerebral ischemia
Stroke/PRIND/TIA 3 (9%)/1 (3%)/0 47 (10%)/2 (4%)/2 (4%) P>.05*
Laboratory data
Creatinine (mg/dL) 1.5  0.7 (0.7–3.4) 1.2  0.7 (0.5–8.2) P ¼ .016y
Pro–BNP (pg/mL) 16,440  19,050 (687–77,019) 4527  6621 (10–50,678) P ¼ .008y
Preoperative risk score
euroSCORE (logistic,%) 59  27 (13–97) 35  19 (12–95) P<.05y
STS mortality score (%) 35  28 (4–90) 16  13 (1–82) P<.05y
CABG, Coronary artery bypass grafting; AVR, aortic valve replacement; MVS, mitral valve surgery; PRIND, prolonged reversible ischemic neurologic deficit; TIA, transient is-
chemic attack; BNP, B-type natriuretic peptide; euroSCORE, European System for Cardiac Operative Risk Evaluation; STS, Society of Thoracic Surgeons. *Fisher exact test.
yt test. zLong-term use of bronchodilators or steroids for lung disease. xApico-descendent conduit (21mm, St JudeMedical Inc, St Paul,Minn) presenting with severe calcification
and aortic valve insufficiency.
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Mann-WhitneyU test and the unpaired sample t test to discern significance.
The log-rank test was used for survival analysis (Kaplan-Meier curves).RESULTS
The technical procedure was performed using the stan-
dard technique in all patients.15 CPB was used in 35 cases:
in 13 patients with preoperative cardiogenic shock, in 11 pa-
tients with impaired heart function during the procedure, in
7 patients with severely impaired left ventricular function
(LVEF, 17%  6%; range, 10%–30%), in 3 patients
with concomitant surgical procedures, and in 1 patient
with impaired right ventricular function.Echocardiographic Data
Preoperative echocardiographic data showed significant
differences in left ventricular function between the 2 groups
(Table 2). In group I, the left ventricular end-diastolic diam-
eter was significantly higher than in group II (LV end-
diastolic diameter: group I: 56  10.2 mm [range, 38–80
mm], group II: 49  7 mm [range, 30–73 mm] [P<.05]),
and the ejection fraction was significantly lower (group I:
32%  19.1% [range, 10%–70%], group II: 51  13%
[range, 10%–70%] [P<.05]). Neither the aortic valve or-
ifice area nor the diameter of the aortic annulus differedThe Journal of Thoracic and Cabetween the groups. The transvalvular aortic valve gradient
differed between the groups because in group I the ejection
fraction was significantly lower (Table 2). Although the de-
gree of mitral valve insufficiency did not differ, patients
with previous heart surgery (group I) more often had pulmo-
nary hypertension and a higher degree of tricuspid valve in-
sufficiency (Tables 1 and 2).
Postoperatively, the transvalvular gradient was low be-
cause of the special design of the valve and did not differ be-
tween the 2 groups (Table 2). Central and paravalvular
regurgitation are special characteristics in transcatheter
valve implantation. Therefore, it is not surprising that post-
operative echocardiographic examinations showed slight
central incompetence in 2 patients in group I (6%) and 50
patients in group II (10%). Minimal paravalvular leakage
was seen in 17 patients (49%) in group I and 184 patients
(39%) in group II (P>.05). The paravalvular regurgitation
was mostly of grade I or less; only in a few patients was it
between grades I and II. No patients in group I had insuffi-
ciency of grade II or more.
Procedural and Postprocedural Course
The technical success rate was 94% (33/35) in group I
and 100% (477/477) in group II. One patient in group I de-
veloped an annulus rupture during valve liberation, and 1rdiovascular Surgery c Volume 145, Number 3 759
TABLE 2. Echocardiographic data (mean ± standard deviation, range)
Group I Group II Test
Preoperative
Left ventricular end-diastolic diameter (mm) 56  10.2 (38–80) 49  7 (30–73) P<.05*
LVEF (%) 32  19.1 (10–70) 51  13 (10–70) P<.05*
Aortic valve
Insufficiency (degree) 1.1  0.7 (0–3) 0.9  0.7 (0–4) P>.05y
Orifice area (cm2) 0.7  0.3 (0.3–1.8) 0.7  0.2 (0.3–1.4) P>.05y
Diameter of aortic annulus (mm) 23  1.7 (18–26) 23  1.6 (18–29*) P>.05y
Gradient max (mm Hg) 53  23.2 (20–106) 74  19 (14–159) P<.05*
Gradient mean (mm Hg) 35  17.4 (10–84) 49  14 (7–100) P<.05*
Mitral valve
Insufficiency (degree) 1.3  0.7 (0–3) 1.1  0.6 (0–3) P>.05y
Tricuspid valve
Insufficiency (degree) 1.3  1.1 (0–4) 0.6  0.7 (0–3.5) P ¼ .008y
Postoperative
Central AVI (degree) 2 (6%) 50 (10%) P>.05y
Degree 0–I 1 29 P>.05z
Degree I 1 19 P>.05z
Degree I–II 2 P>.05z
Degree II
Paravalvular AVI (degree) 17 (49%) 184 (39%) P>.05y
Degree 0–I 7 91 P>.05z
Degree I 6 68 P>.05z
Degree I–II 3 21 P>.05z
Degree II 1 4 P>.05z
Aortic valve gradient
Max (mm Hg) 8  3.4 (4–15) 9  5 (0–40) P>.05y
Mean (mm Hg) 4  1.7 (2–7) 5  2.5 (1–20) P>.05y
LVEF, Left ventricular ejection fraction; AVI, aortic valve implantation. *Mann-Whitney U test. yt test. zFisher exact test.
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tient with reoperation). Even in group II, the success rate
was 100%; in addition, 1 patient developed a type A dissec-
tion, which was successfully treated by placement of an un-
covered aortic endostent.16 The patient’s postoperative
course was uneventful. In group I, 3 patients received a Cor-
eValve (26 mm in 1 patient and 29 mm in 2 patients), and 32
patients received an Edwards SAPIEN valve (23 mm in 9
patients, 26 mm in 20 patients, and 29 mm in 3 patients).
In group II, 50 patients received a CoreValve (29 mm valve)
and 427 patients received an Edwards SAPIEN valve (23
mm in 135 patients, 26 mm in 258 patients, and 29 mm in
34 patients). There were no statistically significant
differences.
Peripheral cannulation for CPB was performed in 26 pa-
tients. The mean bypass time was 64  63 minutes (range,
6–257 minutes). However, central cannulation via median
sternotomy was performed in 9 patients. In these patients,
the mean bypass time was 227  165 minutes (range,
77–628 minutes). The mean CPB time was 23 27 minutes
(range, 6–83 minutes), significantly lower in patients with
elective bypass than in patients with extracorporeal circula-
tion because of impaired heart function during the proce-
dure (154  91 minutes; range, 26–316 minutes), in
patients presenting preoperatively in cardiogenic shock760 The Journal of Thoracic and Cardiovascular Surg(111  61 minutes; range, 43–172 minutes), or in patients
with concomitant surgical procedures (121  173 minutes;
range, 12–628 minutes) (P<.05). An IABP was placed pre-
operatively in 2 patients, and an IABP was necessary in 4
patients at the end of the procedure.
Length of Stay
Because of the patients’ multimorbidity, they required
a long postoperative in-hospital stay. The mean intensive
care unit stay was 4.1  6.7 days (range, 0.2–38 days) in
group I and 1.8  1.7 days (range, 0.6–9.8 days) in group
II. The total length of in-hospital stay was 29.6  19 days
(range, 3–134 days) in group I and 10.1  4 days (range,
4–19 days) in group II. The intensive care unit and in-
hospital stays were significantly longer in group I (P<.05).
Preoperative and Postoperative Stroke Rate
Preoperatively, in group I, 3 patients had a history of
stroke and 1 patient had a prolonged reversible ischemic
neurologic deficit (PRIND), whereas in group II, 47 patients
had previous stroke, 2 patients had a PRIND, and 2 patients
had a transitory ischemic attack. Postoperative clinical ex-
amination showed that in group I, 1 patient had a new stroke
and that in group II, 2 patients had a stroke, 1 patient pre-
sented with a PRIND, and 8 patients had signs of a transientery c March 2013
TABLE 3. Operative data (mean ± standard deviation, range)
Group I Group II Test
No. of patients (n) 35 477
Technical success rate 33 (94%) 477 (100%) P ¼ .045*
On-pump surgery 35 (100%) —
CoreValve (Medtronic Inc, Minneapolis, Minn) 3 50 P>.05*
Size: 26/29/31 mm 1/2/— —/29/—
Edwards SAPIEN valve (Edwards Lifesciences, Irvine, Calif) 32 427 P>.05*
Size: 23/26/29 mm 9/20/3 135/258/34
Pacemaker implantation
DDD/VVI —/2 (6%) 16 (3%)/22 (5%) P>.05*
Reason for CPB
Cardiogenic shock 13 (37%) —
Intraprocedural impaired heart function 11 (31%) —
Impaired LV function 7 (20%) —
Impaired RV function 1 (3%) —
Concomitant surgical procedure 3 (9%) —
CPB (peripheral)
No. of patients 26 (74%) —
Bypass time 64  63 (6–257) —
CPB (central)
No. of patients 9 (26%) —
Bypass time 227  165 (77–628) —
Time of hospitalization (d)
Length of stay on ICU 4.1  6.7 (0.2–38) 1.8  1.7 (0.6–9.8) P<.05y
Total length of stay 29.6  19 (3–134) 10.1  4 (4–19) P<.05y
Mortality
30-d mortality 7 (20%) 22 (4.83%) P<.05z
Survival
6-mo survival 54% 87% P<.05z
1-y survival 46% 84% P<.05z
1.5-y survival 46% 80% P<.05z
2-y survival 40% 72% P<.05z
CPB, cardiopulmonary bypass; LV, left ventricular; RV, right ventricular; ICU, intensive care unit. *Fisher exact test. yMann-Whitney U test. zLog-rank test (P<.05).
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the 2 groups.
Cardiac Pacemaker
In the case of postoperative atrioventricular block degree
III for more than 3 days, a cardiac pacemaker was im-
planted. In group I, 2 patients (6%) required pacemaker im-
plantation postoperatively (both received an Edwards
SAPIEN valve), and in group II, 38 patients (8%) required
pacemaker implantation postoperatively (12 patients re-
ceived a CoreValve and 26 patients received an Edwards
SAPIEN valve). Although 24% of patients with a Core-
Valve required pacemaker implantation, 6% of patients
with an Edwards SAPIEN valve required pacemaker im-
plantation. There was no statistically significant difference
between groups I and II.
Survival
The 30-day mortality was 20% in group I and 4.8% in
group B. The 1-year survival was 46% in group I and
84% in group B. The difference was statistically significantThe Journal of Thoracic and Ca(Table 3, Figure 1). In group I, during the first 30 days, 7 pa-
tients died: myocardial failure in 3 patients, septicemia in 2
patients, and intraoperative death in 2 patients. Five of these
7 patients presented with preoperative cardiogenic shock; 1
patient had severe central aortic prosthesis insufficiency,
making a second Edwards SAPIEN valve implantation nec-
essary; and 1 patient had a type A dissection, making ster-
notomy necessary. No patient with concomitant heart
surgery died.
In group II, the reason for early postoperative death was
mostly septicemia (7 patients), followed bymyocardial fail-
ure (4 patients), right-sided heart failure (3 patients), embo-
lism (2 patients), and other reasons, for example, left
ventricle perforation and rupture of an abdominal aortic an-
eurysm (7 patients).DISCUSSION
In patients with advanced heart failure, the operative risk
is elevated during conventional aortic valve replacement.
The mortality ranged from 3% to 30%.7-9,14 TAVI has
been introduced to reduce the surgical risk in patientsrdiovascular Surgery c Volume 145, Number 3 761
FIGURE 1. Survival (Kaplan-Meier curves, log-rank test:<.05).
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CPB during TAVI allows the procedure to be performed
with greater safety in patients with advanced heart failure.
As presented in an earlier publication,14,17,18 TAVI can be
performed successfully in patients with advanced heart
failure. Our group showed that the postoperative course in
patients with left ventricular function less than 25% is
prolonged, but the midterm survival is not influenced.14 In
this cohort, an elective femoro-femoral bypass was used
in 43% of patients. As reported in 2010,4 our standard insti-
tutional policy is to consider the use of elective femoro-
femoral CPB in patients with severe cardiogenic shock,
poor left ventricular function (LVEF, 10%–20%), or both.
Nevertheless, no literature as yet exists presenting expe-
rience with the elective and urgent use of CPB during TAVI.
CPB is rarely necessary for TAVI, but it is a prerequisite for
the procedure to have the heart-lungmachine ready to use in
the operating room, and it is an important part of the safety
net,17 although not all patients placed on CPB during the
procedure need the support. Nevertheless, its elective use
increases the safety in critically ill patients to maintain he-
modynamic stability during the phases of rapid pacing and
to prevent manual cardiopulmonary resuscitation, because
the postoperative course of these patients is unfavorable.
We consider the use of the heart-lung machine in the fol-
lowing 3 ways: (1) placement of the connecting tubes on the
table, (2) cannulation of the femoral vessels without starting
up the heart-lung machine, and (3) valvuloplasty and valve
deployment under a short duration of CPB.
The first strategy may save time if complications occur,
for example, in patients with a small distance of the coro-
nary ostia to the aortic annulus or in patients with severe762 The Journal of Thoracic and Cardiovascular Surgpulmonary hypertension. The second strategy seems to be
justified in patients with markedly reduced left ventricular
function (ie, LVEF<25%) or severe regurgitation of the
atrioventricular valves. If hemodynamic instability (refrac-
tory to high-dose catecholamine administration) occurs, the
heart-lung machine may be started within 1 second after
simply removing the clamps on the connecting tubes. The
third strategy is considered at Deutsches Herzzentrum Ber-
lin in patients with poor left ventricular performance
(LVEF, 10%–20%), cardiogenic shock, or decompensated
right-sided heart failure with an enlarged right ventricle.
The progression of rapid pacing into ventricular fibrillation
is often difficult to manage. The primary use of CPB instead
of its secondary use on an emergency basis may provide su-
perior results.
We have shown that the elective use of extracorporeal cir-
culation (in some cases for several minutes only) allows
TAVI to be performed in patients with severely depressed
myocardial function (ejection fraction<20%). Patients in
cardiogenic shock and with concomitant heart disease can
safely undergo operation. Therefore, our guidelines for par-
ticular situations with regard to patient selection, use of
CPB, and IABP are as follows:
1. ‘‘No exclusion’’ policy: All patients with an STS score
of 10 or more are evaluated as candidates for treatment
regardless of comorbidities and clinical status, for exam-
ple, profound shock (except patients with active endo-
carditis), if it is technically possible to perform the
procedure in terms of the annular size.
2. Elective femoro-femoral CPB is considered in patients
with severe cardiogenic shock, poor left ventricular
function (LVEF, 10%–20%), or enlarged right ventricle
with severe pulmonary hypertension.
3. The IABP is considered in high-risk patients with de-
pressed hemodynamic condition.
CPB is rarely necessary for TAVI. Nevertheless, its use
allows the procedure to be performed safely in patients
with severely depressed left ventricular function (ejection
fraction<20%) with or without additional severe mitral
valve regurgitation, coronary artery disease, severe pulmo-
nary hypertension with an enlarged right ventricle, or unsta-
ble hemodynamics. These patients might develop
ventricular fibrillation during or immediately after the ces-
sation of rapid pacing for balloon dilatation of the native
valve or valve deployment.
CONCLUSIONS
From our initial experience, TAVI with CPB seems
to provide better results than medical treatment or conven-
tional aortic valve replacement, which carries a relatively
high operative mortality in these specific pa-
tients.7-9,12,14,19,20 In addition, it emphasizes that TAVI
should be performed only in cooperation betweenery c March 2013
Drews et al Acquired Cardiovascular Diseasecardiologists and cardiac surgeons in a hybrid operating
room in a completely sterile environment with potential
elective use of the heart–lung machine.
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